SCHEMBL30775401

SCHEMBL30775401

CN1CCN(c2ccnc(-c3cccc4c3CNC4)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 5/20 0.49
JAK2 O60674 1/20 0.42
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
ADRA2C P18825 1/20 0.40
FLT3 P36888 3/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CDK7 P50613 1/20 0.39
CCNH P51946 1/20 0.39
MNAT1 P51948 1/20 0.39
MET P08581 1/20 0.38
CYP1A2 P05177 2/20 0.38
PLOD2 O00469 1/20 0.38
PLOD3 O60568 1/20 0.38
PLOD1 Q02809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775292 0.82 HRH4 (0.48) HRH4JAK2MEN1GLAGAA
SCHEMBL2383417 0.77 CYP1A2 (0.63) HRH4MEN1GLAGAAKMT2A
SCHEMBL2386172 0.77 HRH4 (0.56) HRH4MEN1GLAGAAKMT2A
SCHEMBL2385662 0.76 HRH4 (0.55) HRH4FLT3CCNE1CDK2CDK1
SCHEMBL2383926 0.76 HRH4 (0.52) HRH4MEN1GLAGAAKMT2A
SCHEMBL2384160 0.72 HRH4 (0.68) HRH4MEN1GLAGAAKMT2A
SCHEMBL6027496 0.71 HRH4 (0.56) HRH4MEN1GLAGAAKMT2A
SCHEMBL2386270 0.71 HRH4 (0.47) HRH4MEN1KMT2AFLT3CCNE1
SCHEMBL4214496 0.70 HRH4 (0.54) HRH4MEN1GLAGAAKMT2A
SCHEMBL2385751 0.70 HRH4 (0.61) HRH4JAK2MEN1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR HRH4 3323/4885JAK2 4317/4885MEN1 1984/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR HRH4 3323/4885JAK2 4317/4885MEN1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.